

Sustainability Accounting Standards Board

The Sustainability Accounting Standards Board (SASB) has identified the ESG issues that are most likely to affect the long-term financial performance the typical company within a specific industry. Below are the disclosure topics and accounting metrics associated with our industry, Biotechnology & Pharmaceuticals, with two additional metrics important our firm.

Many of the accounting metrics in the standard do not apply directly to our operations because while we provide technologies used in the development of drug therapies, diagnostics and vaccines, we do not manufacture or market those final products. For topics included in the standard that are not applicable to our business, we indicate where you can find related information within this report.

Topic	Code	Accounting Metric	Response
Safety of Clinical Trial Participants	HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	These accounting metrics are not applicable to our business. For related content on this topic, please see: Product Quality Assurance .
	HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	
Access to Medicines	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	These accounting metrics are not applicable to our business. For related content on this topic, please see: Impact on Society .
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	
Affordability & Pricing	HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	These accounting metrics are not applicable to our business. For related content on this topic, please see: Product Quality Assurance .
	HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	
	HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	

Sustainability Accounting Standards Board

(Continued)

Topic	Code	Accounting Metric	Response
Drug Safety	HC-BP-250a.1	List of products in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	These accounting metrics are not applicable to our business. We sell an API for clinical use to customers who create the final drug product. FDA enforcement actions are relevant to those customers. For related content on this topic, please see: Product Quality Assurance .
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	
	HC-BP-250a.3	Number of recalls issued; total units recalled	
	HC-BP-250a.4	Total amount of product accepted for takeback, reuse or disposal	
	HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	
Counterfeit Drugs	HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	All Maravai business units operate under a Quality Management System, enabling tracing of raw materials purchased and received, as well as products manufactured and shipped to customers. Robust product specifications define all products and are verified by internal quality control processes. In 2022, TriLink obtained a Customs Trade Partnership Against Terrorism (CTPAT) certification, which demonstrates our implementation of security best practices across the supply chain and the increased prevention of counterfeiting. For more content on this topic, please see: Supplier Assessment .
	HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	Traceability is enabled to our end customer through our Quality Management System and Lot numbering system to protect against counterfeiting. Customers are notified of counterfeit risk through this system. For more content on this topic, please see: Supplier Assessment .
	HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	Zero actions led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products.

Sustainability Accounting Standards Board

(Continued)

Topic	Code	Accounting Metric	Response
Ethical Marketing	HC-BP-260a.3	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	The accounting metric is not applicable to our business.
	HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	
Employee Recruitment, Development & Retention	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	Maravai has a partnership with PATHways to STEM through Enhanced Access and Mentorship (PATHS) Program at UC San Diego and participates in STEM-related job fairs at universities in San Diego. Maravai provides a competitive compensation package and comprehensive benefits for employees, as well as on-the-job training and advancement opportunities. Through robust annual employee surveys and action planning, Maravai aims to continue to engage and invest in its team members.
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Not Disclosed. For more information on employee engagement and retention, please see: Employee Engagement .
Supply Chain Management	HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	TriLink's high-risk suppliers are audited by a third-party once every three years. For more information on this topic, please see: Product Quality Assurance .
Business Ethics	HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Zero monetary losses were incurred in 2022.
	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	The accounting metric is not applicable to our business. For more information related to this topic, please see: Business Ethics .

Sustainability Accounting Standards Board

(Continued)

Topic	Code	Accounting Metric	Response
Data Security	SV-PS-230a.2	Number of data breaches, percentage involving customers' confidential business information or personally identifiable information, and number of customers affected.	No known breaches of customer data occurred during the reporting year.
	SV-PS-230a.3	Description of policies and practices related to collection, usage and retention of customer information	Maravai provides a data privacy notice on all websites and does not sell, license or share personal information with unaffiliated third parties for marketing purposes. For more information, visit Maravai's website's Privacy Policy (https://www.maravai.com/privacy-notice) or contact us at privacy@maravai.com .
Activity Metric	HC-BP-000.A	Number of patients treated	The accounting metric is not applicable to our business. For related content on this topic, please see: Product Innovation .
	HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	